Premium
Distinguishing features of primary hyperparathyroidism in patients with breast cancer
Author(s) -
Axelrod Deborah M.,
Bockman Richard S.,
Wong George Y.,
Osborne Michael P.,
Kinne David W.,
Brennan Murray F.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19871001)60:7<1620::aid-cncr2820600733>3.0.co;2-3
Subject(s) - medicine , primary hyperparathyroidism , breast cancer , incidence (geometry) , cancer , stage (stratigraphy) , hyperparathyroidism , disease , population , oncology , paleontology , physics , environmental health , optics , biology
Thirty‐five women with breast cancer and primary hyperparathyroidism (1°HFT) were admitted to Memorial Hospital during a 25‐year period. The incidence of primary hyperparathyroidism in the breast cancer patients was similar to the incidence in the total patient population at Memorial Sloan‐Kettering Cancer Center (0.15% and 0.14%, respectively). The patients with 1°HPT disease had clinical findings which distinguished them from those patients with cancer‐related hypercalcemia. Eighty percent of the breast cancer patients with primary hyperparathyroidism had earlier stage disease (Stage 0, Stage 1, Stage 2); whereas 97% of the patients with breast cancer and hypercalcemia (not due to 1°HPT) had advanced disease. There appeared to be a trend towards improved survival in the breast cancer patients with primary hyperparathyroidism when compared to patients of similar stage of disease who did not have parathyroid disease.